Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents

RONGHUI Lin; Peter J Connolly; Robert H Gruninger; Mary Adams; Angel R FUENTES-PESQUERA; Lee M Greenberger; YANHUA LU; George Chiu; SHENGJIAN LI; YANG YU; SHENLIN Huang; XUN LI; Stuart L Emanuel; Steven A Middleton

doi:10.1016/j.bmcl.2007.05.029

Back

Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents

Journal article

Peer reviewed

Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents

RONGHUI Lin, Peter J Connolly, Robert H Gruninger, Mary Adams, Angel R FUENTES-PESQUERA, Lee M Greenberger, YANHUA LU, George Chiu, SHENGJIAN LI, YANG YU, …

Bioorganic & medicinal chemistry letters, Vol.17(15), pp.4297-4302

01/08/2007

DOI: https://doi.org/10.1016/j.bmcl.2007.05.029

PMID: 17532631

Abstract

Antineoplastic agents

Biological and medical sciences

General aspects

Medical sciences

Pharmacology. Drug treatments

Metrics

1 Record Views

See more details

Details

Title: Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents
Creators - without role: RONGHUI Lin - Johnson & Johnson
Peter J Connolly - Johnson & Johnson
Robert H Gruninger - Johnson & Johnson
Mary Adams - Johnson & Johnson
Angel R FUENTES-PESQUERA - Johnson & Johnson
Lee M Greenberger - Johnson & Johnson
YANHUA LU - Johnson & Johnson
George Chiu - Johnson & Johnson
SHENGJIAN LI - Johnson & Johnson
YANG YU - Johnson & Johnson Pharmaceutical Research & Development L.L.C., 1000 Route 202, PO Box 300, Raritan, NJ 08869, United States
SHENLIN Huang - Johnson & Johnson
XUN LI - Johnson & Johnson
Stuart L Emanuel - Johnson & Johnson
Steven A Middleton - Johnson & Johnson
Publication Details: Bioorganic & medicinal chemistry letters, Vol.17(15), pp.4297-4302
Publisher: Elsevier
Identifiers: 9944250808331
Academic Unit: King Abdullah University of Science & Technology
Language: English
Resource Type: Journal article